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The prevalence of macrolide–lincosamide–strep-
togramin (MLS) resistance phenotypes was
determined among erythromycin-resistant
Staphylococcus epidermidis isolates collected at the
Bone Marrow Transplant Centre, Tunisia during
2002. The erm(A), erm(B), erm(C), msrA, mefA and
icaA genes were detected by PCR. The vga, vgb
and vat genes were amplified from pristinamycin-
resistant isolates. The icaA gene was detected in
76.5% of 34 isolates examined in detail. The
erm(C) (53%) and erm(A) (32%) genes predomin-
ated because of clonal dissemination, followed by
msrA (15%). Gene distribution was related to the
methicillin resistance pattern. The vga gene was
present in combination with erm(A) in three
isolates.
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Coagulase-negative staphylococci are the bacteria
isolated most frequently from the blood cultures
of febrile neutropenic patients, particularly in
association with the use of intravenous catheters
[1]. Resistance to macrolides is conferred either by
methylases, encoded by erm genes that modify the
ribosomal target of macrolides [2], or by efflux
pumps, encoded by the msrA gene. Ribosomal
methylation results in cross-resistance to macro-
lide, lincosamide and streptogramin B antibiotics
(MLSB phenotype) [3], and can be expressed
either constitutively (cMLSB) or inducibly (iMLSB)
[4]. Macrolide efflux is characterised by resistance
to 14- and 15-membered-ring macrolides (M
phenotype) [5]. The aims of the present study
were to determine the incidence and patterns of
antimicrobial resistance among Staphylococcus epi-
dermidis isolates from Tunisia, to correlate eryth-
romycin and pristinamycin resistance with the
presence of the MLS resistance genes erm(A),
erm(B), erm(C), msrA, mefA, vga, vgb and vat, to
search for the presence of the icaA gene in these
isolates, and to assess their molecular epidemiol-
ogy.
During 2002, 55 S. epidermidis isolates from
blood cultures and 22 isolates from the intravas-
cular catheters of 34 patients with haematological
cancer at the Centre National de Greffe de Moelle
Osseuse, Tunis, Tunisia were analysed. Isolates
were identified using conventional methods and
the ID-32 Staph system (bioMe´rieux, Marcy l’Eto-
ile, France). Susceptibility to antibiotics was tested
using the agar diffusion technique. MICs were
determined using the agar dilution method
according to French guidelines [6]. Resistance
phenotypes of erythromycin-resistant isolates
were determined using erythromycin, spiramy-
cin, clindamycin, lincomycin and pristinamycin
disks. Thirty-four erythromycin-resistant isolates
were chosen randomly for PCR amplification of
macrolide resistance genes [7–9] using the prim-
ers shown in Table 1. A multiplex PCR assay was
used to amplify erm(A), erm(C) and msrA [8]; a
duplex PCR was used to amplify erm(B) and mefA
[10]; and individual PCRs were used to detect
vga, vgb, vat [11] and icaA [9]. Pulsed-field gel
Corresponding author and reprint requests: A. Ben Hasen,
Laboratory, National Bone Marrow Transplant Centre, Tunis,
Tunisia
E-mail: assiabenhassen@yahoo.fr
Research Notes 103
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 13, 86–108
electrophoresis was performed essentially as des-
cribed by Bannerman et al. [12].
Resistance was detected to erythromycin (62%
of isolates), oxacillin (51%), gentamicin (61%),
lincomycin (60%), ofloxacin (60%) and rifampicin
(51%). The rates of resistance to teicoplanin
(6.5%) and pristinamycin (4%) were low. No
resistance was detected to vancomycin. The rates
of resistance to penicillin G and oxacillin were
similar to those observed in Canada [8,13]. Eryth-
romycin resistance was higher in Tunis than in
the UK (47.5%) [14] and Ontario, Canada (54%)
[1], probably because of the high selective anti-
microbial pressure. The prevalence of pristina-
mycin resistance is usually low in most French
(<5%) and Danish (14%) hospitals [15,16], but can
be higher in hospitals where pristinamycin is
used extensively, as reported previously for an
Algerian hospital (20%) [11]. Methicillin-resistant
S. epidermidis isolates (Meti-R) were significantly
more often resistant to MLS antibiotics (82% to
erythromycin, 79.5% to clindamycin) than were
Meti-S isolates (39.5% and 16%, respectively;
p <0.001). Similar findings were revealed by a
study in the USA [17].
Five phenotypes were observed among the 48
erythromycin-resistant isolates. Among the total
of 77 isolates, 34 (44%) displayed constitutive and
one (1%) inducible MLSB resistance. Four (5%)
isolates displayed resistance to MLS antibiotics,
including streptogramins A and B (MLSA+B phe-
notype), while six (8%) had the M phenotype and
three (4%) displayed resistance to erythromycin
and lincomycin (M+L phenotype). The iMLSB
phenotype is the most prevalent phenotype found
in Denmark (64%) [16]. In the present study, the
M phenotype was found in only four (12%)
isolates. This phenotype has been observed at
similar frequencies in other countries, e.g., 11% in
France [11] and 14% in Denmark [16].
Among the 34 erythromycin-resistant isolates
that were studied further, 25 displayed the cMLSB
phenotype, one the iMLSB phenotype, three the
MLSA+B phenotype, four the M phenotype, and
one the M+L phenotype. The distribution of the
erythromycin resistance genes in relation to the
erythromycin resistance phenotypes is summar-
ised in Table 2. The most prevalent resistance
determinants were erm(C)-like (53%), followed by
erm(A)-like (32%) and msrA-like (15%). This
distribution is similar to that observed in other
countries [2,8,11,16,18]. The erm(B) and mefA
genes were not detected. The erm(B) gene was
encountered in only 0.5% of S. epidermidis isolates
in a previous study from Canada [8], but was
present in 7.2% of isolates from the UK, albeit
these were exclusively animal isolates [19]. The
Table 1. Primers used for PCR
amplificationPrimer name Primer sequence (5¢)3¢) Gene
Size of PCR
product (bp) Reference
Erm AO TAT CTT ATC GTT GAG AAG GGA TT erm(A) 139 [3]
Erm AR CTA CAC TTG GCT TAG GAT GAA A
Erm BO CTA TCT GAT TGT TGA AGA AGG ATT erm(B) 142 [3]
Erm BR GTT TAC TCT TGG TTT AGG ATG AAA
Erm CO CTT GTT GAT CAC GAT AAT TTC C erm(C) 190 [3]
Erm CR ATC TTT TAG CAA ACC CGT ATT C
Msr AO TCC AAT CAT TGC ACA AAA TC msrA 163 [3]
Msr AR AAT TCC CTC TAT TTG GTG GT
Vga 1 CCA GAA CTG CTA TTA GCA GAT GAA vga 470 [9]
Vga 2 AAG TTC GTT TCT CTT TTC GAC G
Vgb 1 ACT AAC CAA GAT ACA GGA CC vgb 734 [9]
Vgb 2 TTA TTG CTT GTC AGC CTT CC
Vat 1 CAA TGA CCA TGG ACC TGA TC vat 619 [9]
Vat 2 CTT CAG CAT TTC GAT ATC TCC
Mef3 TAA TAG GAT TTA GTT CCC AAA CGG mefA 457 [15]
Mef4 GCA GTA TCA TTA ATG ACT AGT CCC
Ica AF GAC CTC GAA GTC AAT AGA GGT icaA 814 [18]
Ica AR CCC AGT ATA ACG TTG GAT ACC
Table 2. Distribution of MLS resistance phenotypes
according to resistance genotype
Resistance
phenotype
Number (%) of isolates resistant by
Target modification Efflux
erm(A) erm(C) msrA Total
cMLSB 8 (23) 17 (50) 0 25 (73)
d MLSB 0 1 (3) 0 1 (3)
MLSA+B 3 (9) 0 0 3 (9)
M+L 0 0 1 (3) 1 (3)
M 0 0 4 (12) 4 (12)
Total 11 (32) 18 (53) 5 (15) 34 (100)
cMLSB, cross-resistance to erythromycin, spiramycin and lincomycin; d MLSB,
dissociated MLSB resistance (resistance to erythromycin and spiramycin and
susceptibility to lincomycin); MLSA+B, resistance to MLS, including streptogramins
A and B; M+L, resistance to erythromycin and lincomycin; M, efflux phenotype.
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mefA gene has been found, either alone or
together with erm genes, in coagulase-negative
staphylococci [18]. No association of different erm
genes was found in the present study, although
this has been reported previously [18,19]. The
MIC of erythromycin varied between 32 and
>1024 mg ⁄L for the isolates harbouring erm(A) or
erm(C), and between 16 and 32 mg ⁄L for those
harbouring msrA.
Meti-R isolates harboured significantly more
erm genes (p <0.001), particularly erm(C)
(p <0.001), than Meti-S isolates, but msrA was
not detected. In France, erm(A)-like and erm(C)-
like genes were observed more frequently [11],
while msrA was predominant among Meti-R
isolates in the UK [19]. The erm(A) gene was
detected in combination with vga in three isolates
with the MLSA+B phenotype (pristinamycin
MIC90 = 1 mg ⁄L), as reported by Lina et al. [11].
The vgb and vat genes were not detected in
pristinamycin-resistant isolates, but have been
detected previously in a limited number of
isolates [11]. A 100% correlation was observed
between the MLS resistance phenotypes and
genotypes (Table 2), although Martineau et al.
[8] have previously reported some discrepancies.
The icaA gene was amplified from 76.5% of the
erythromycin-resistant isolates, and from all but
one of the catheter isolates. This finding agrees
with recent studies in France [20] and Germany
[9]. It has been hypothesised that the presence of
the ica gene locus is related to the potential
virulence of a strain [20]. Two pulsed-field gel
electrophoresis clones of S. epidermidis predomin-
ated in the present study: one clone with the
cMLSB phenotype, containing erm(A) in all iso-
lates, and a second clone containing erm(C) in 12
of 18 isolates. The five msrA strains were not
clonally related. Clonal spread of methicillin-
resistant S. epidermidis strains has been reported
previously in Denmark [16].
In conclusion, the S. epidermidis isolates ana-
lysed in the present study showed a high fre-
quency of erythromycin resistance, belonged
predominantly to the cMLSB phenotype, and
had disseminated in the form of two, erm(A)- or
erm(C)-containing, clones.
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A B S T R A C T
A vancomycin-resistant Enterococcus faecium iso-
late from the urine of a liver transplant patient in
Stockholm was found to contain a vanD gene. The
sequence of the vanD PCR product shared 100%
identity with the vanD5 allele. The isolate was
resistant to a relatively high level of vancomycin
(128 mg ⁄L) and a low level of teicoplanin
(4 mg ⁄L). This is the first VanD-type vancomy-
cin-resistant E. faecium isolate reported in Swe-
den. The emergence of this strain reinforces the
necessity of infection control efforts to interrupt
the spread of these organisms.
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Since the first vancomycin-resistant clinical iso-
lates of Enterococcus spp. were reported in Europe
during 1988 [1,2], vancomycin-resistant entero-
cocci have emerged worldwide and have become
an increasing problem in clinical settings [3,4].
However, the incidence of vancomycin-resistant
enterococci is still low in Sweden (http://
www.strama.se). Resistance to vancomycin re-
sults from the production of low-affinity pepti-
doglycan precursors ending in D-Ala-D-Lac
(VanA, VanB and VanD) or D-Ala-D-Ser (VanC,
VanE and VanG), and from the elimination of
high-affinity precursors [5,6]. Six types of vanco-
mycin resistance have been characterised in en-
terococci, both phenotypically and genotypically.
Five of these types (VanA, B, D, E and G)
correspond to acquired resistance, while VanC is
an intrinsic property of Enterococcus gallinarum
and Enterococcus casseliflavus–Enterococcus flaves-
cens. VanA and VanB are the most common types.
VanE and VanG have been identified in single
strains of Enterococcus faecalis [7,8]. VanD-type
strains are characterised by constitutive resistance
to moderate levels of both vancomycin and
teicoplanin [5,9], and Enterococcus faecium strains
with VanD-type resistance have been reported in
the USA, Canada, Brazil and France [10–15].
The strain (Hyg-39) described in this report was
isolated from the urine of a liver transplant patient
admitted to the intensive care unit of Karolinska
University Hospital Huddinge, Stockholm, Swe-
den during April 2003. The strain was first iden-
tified by standard biochemical tests, and the
identification was then verified by PCR targeting
the ddl (D-Ala:D-Ala ligase) gene of E. faecium.
Antimicrobial susceptibility was determined by
disk-diffusion (Swedish Reference Group for
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